Dr.Vishal Gupta is the Founder & Director of VG-ADVANTAGE Diabetes Thyroid & Endocrine Center & Author of Beyond Type 2 Diabetes. After returning for the UK having trained at the prestigious North-East Thames London Group of Hospital ‘St Bart’s & Royal London NHS Trust & securing the MRCP (UK) degree in 2007, Dr Vishal Gupta envisioned the opening of a holistic under one-roof diabetes, thyroid & endocrine center which eventually took shape in 2014. Since then the center services more than 14,000 patients per year. His motto has been ‘gifting life’. In order to achieve that vision he has lead research from the fore-front that has helped alter existing guidelines and treatment protocols in order to improve patient quality of life/longevity. He wrote a book called “beyond type 2 diabetes” in 2020 which summarises his research and understanding of diabetes addressing difficult to manage conditions like diabetes and infections/immunity/cancer/heart & kidney disease and most of all nutrition. It especially guides healthcare providers to manage heart/renal complication. He founded a national/international endocrine group called ‘InDEA, Indian diabetes endocrine association” that holds a yearly conference with the aim to educate primary and secondary healthcare providers on latest research and outcomes in diabetes & endocrinology.
Dr Vishal Gupta is considered as an authority in the field of Endocrinology & Diabetes & is a reputed clinical and translational researcher in obesity and type 2 diabetes and has over 100 publications. His patient-oriented research work has delineated the metabolic and molecular mechanisms of insulin resistance in the pathogenesis of type 2 diabetes. Dr Vishal Gupta has extensive experience in health plan clinical operations, complex case management, quality and outcome-based strategy execution, value-based care modelling, digital health technology implementation, and integrating physical and behavioral health. Dr Vishal Gupta’s research interests involve chronic complications of diabetes, particularly diabetic neuropathy, diabetic foot complications, diabetic kidney disease and cardiovascular disease, and novel technologies for treating type 2 diabetes.
No comment